Peri-implant bone regeneration using recombinant human bone morphogenetic protein-2 in a canine model: A dose-response study

Dimitris N. Tatakis, Alexander Koh, Lisa Jin, John M. Wozney, Michael D. Rohrer, Ulf M E Wikesjö

Research output: Contribution to journalArticle

79 Citations (Scopus)

Abstract

The objective of this study was to evaluate the effect of recombinant human bone morphogenetic protein-2 (rhBMP-2) dose on alveolar ridge augmentation and dental implant osseointegration. Bilateral, 5 mm supraalveolar, peri-implant defects were surgically created in 6 beagle dogs. rhBMP-2 (0.05. 0.1 or 0.2 mg/ml) in an absorbable collagen sponge (ACS) carrier was molded around the fixtures and wounds were closed. Treatment variations were alternated between animals (incomplete block design). Animals were sacrificed at week 8 postsurgery. Nine of twelve jaw quadrants healed uneventfully. Two jaw quadrants exhibited wound failure by week 4 and one by week 8 postsurgery. Radiographic bone regeneration was observed in defects without wound failure from week 4 postsurgery. Radiolucent voids of variable size and shape were observed and regressed over time. In weeks 6 through 8, there was an apparent increase in bone density and trabecular structure, while bone height and volume decreased. Histometric analysis revealed limited differences in bone regeneration between experimental conditions. Bone regeneration area averaged (±SD) 1.0 ± 0.5, 3.5 ± 1.4 and 2.3 ± 0.4 mm2 for the 0.05. 0.1 and 0.2 mg/ml dose, respectively. There were no significant differences in osseointegration. Osseointegration in newly formed bone averaged 19 ± 4%, 18 ± 10% and 21 ± 6% for the 0.05, 0.1 and 0.2 mg/ml rhBMP-2 sites, respectively. Collectively, the data suggest that there are no dramatic differences in bone induction and osseointegration within the selected dose and observation interval.

Original languageEnglish (US)
Pages (from-to)93-100
Number of pages8
JournalJournal of Periodontal Research
Volume37
Issue number2
DOIs
StatePublished - Jan 1 2002

Fingerprint

Osseointegration
Bone Regeneration
Canidae
Jaw
Bone and Bones
Wounds and Injuries
Alveolar Ridge Augmentation
Dental Implants
Porifera
Bone Density
Collagen
Observation
Dogs
recombinant human bone morphogenetic protein-2

Keywords

  • Bone morphogenetic protein-2
  • Bone regeneration, dental implants
  • Dose-response
  • Osseointegration

ASJC Scopus subject areas

  • Periodontics

Cite this

Peri-implant bone regeneration using recombinant human bone morphogenetic protein-2 in a canine model : A dose-response study. / Tatakis, Dimitris N.; Koh, Alexander; Jin, Lisa; Wozney, John M.; Rohrer, Michael D.; Wikesjö, Ulf M E.

In: Journal of Periodontal Research, Vol. 37, No. 2, 01.01.2002, p. 93-100.

Research output: Contribution to journalArticle

Tatakis, Dimitris N. ; Koh, Alexander ; Jin, Lisa ; Wozney, John M. ; Rohrer, Michael D. ; Wikesjö, Ulf M E. / Peri-implant bone regeneration using recombinant human bone morphogenetic protein-2 in a canine model : A dose-response study. In: Journal of Periodontal Research. 2002 ; Vol. 37, No. 2. pp. 93-100.
@article{cb696582ae7f4cf393d8d70eb53c4a28,
title = "Peri-implant bone regeneration using recombinant human bone morphogenetic protein-2 in a canine model: A dose-response study",
abstract = "The objective of this study was to evaluate the effect of recombinant human bone morphogenetic protein-2 (rhBMP-2) dose on alveolar ridge augmentation and dental implant osseointegration. Bilateral, 5 mm supraalveolar, peri-implant defects were surgically created in 6 beagle dogs. rhBMP-2 (0.05. 0.1 or 0.2 mg/ml) in an absorbable collagen sponge (ACS) carrier was molded around the fixtures and wounds were closed. Treatment variations were alternated between animals (incomplete block design). Animals were sacrificed at week 8 postsurgery. Nine of twelve jaw quadrants healed uneventfully. Two jaw quadrants exhibited wound failure by week 4 and one by week 8 postsurgery. Radiographic bone regeneration was observed in defects without wound failure from week 4 postsurgery. Radiolucent voids of variable size and shape were observed and regressed over time. In weeks 6 through 8, there was an apparent increase in bone density and trabecular structure, while bone height and volume decreased. Histometric analysis revealed limited differences in bone regeneration between experimental conditions. Bone regeneration area averaged (±SD) 1.0 ± 0.5, 3.5 ± 1.4 and 2.3 ± 0.4 mm2 for the 0.05. 0.1 and 0.2 mg/ml dose, respectively. There were no significant differences in osseointegration. Osseointegration in newly formed bone averaged 19 ± 4{\%}, 18 ± 10{\%} and 21 ± 6{\%} for the 0.05, 0.1 and 0.2 mg/ml rhBMP-2 sites, respectively. Collectively, the data suggest that there are no dramatic differences in bone induction and osseointegration within the selected dose and observation interval.",
keywords = "Bone morphogenetic protein-2, Bone regeneration, dental implants, Dose-response, Osseointegration",
author = "Tatakis, {Dimitris N.} and Alexander Koh and Lisa Jin and Wozney, {John M.} and Rohrer, {Michael D.} and Wikesj{\"o}, {Ulf M E}",
year = "2002",
month = "1",
day = "1",
doi = "10.1034/j.1600-0765.2002.00021.x",
language = "English (US)",
volume = "37",
pages = "93--100",
journal = "Journal of Periodontal Research",
issn = "0022-3484",
publisher = "Blackwell Munksgaard",
number = "2",

}

TY - JOUR

T1 - Peri-implant bone regeneration using recombinant human bone morphogenetic protein-2 in a canine model

T2 - A dose-response study

AU - Tatakis, Dimitris N.

AU - Koh, Alexander

AU - Jin, Lisa

AU - Wozney, John M.

AU - Rohrer, Michael D.

AU - Wikesjö, Ulf M E

PY - 2002/1/1

Y1 - 2002/1/1

N2 - The objective of this study was to evaluate the effect of recombinant human bone morphogenetic protein-2 (rhBMP-2) dose on alveolar ridge augmentation and dental implant osseointegration. Bilateral, 5 mm supraalveolar, peri-implant defects were surgically created in 6 beagle dogs. rhBMP-2 (0.05. 0.1 or 0.2 mg/ml) in an absorbable collagen sponge (ACS) carrier was molded around the fixtures and wounds were closed. Treatment variations were alternated between animals (incomplete block design). Animals were sacrificed at week 8 postsurgery. Nine of twelve jaw quadrants healed uneventfully. Two jaw quadrants exhibited wound failure by week 4 and one by week 8 postsurgery. Radiographic bone regeneration was observed in defects without wound failure from week 4 postsurgery. Radiolucent voids of variable size and shape were observed and regressed over time. In weeks 6 through 8, there was an apparent increase in bone density and trabecular structure, while bone height and volume decreased. Histometric analysis revealed limited differences in bone regeneration between experimental conditions. Bone regeneration area averaged (±SD) 1.0 ± 0.5, 3.5 ± 1.4 and 2.3 ± 0.4 mm2 for the 0.05. 0.1 and 0.2 mg/ml dose, respectively. There were no significant differences in osseointegration. Osseointegration in newly formed bone averaged 19 ± 4%, 18 ± 10% and 21 ± 6% for the 0.05, 0.1 and 0.2 mg/ml rhBMP-2 sites, respectively. Collectively, the data suggest that there are no dramatic differences in bone induction and osseointegration within the selected dose and observation interval.

AB - The objective of this study was to evaluate the effect of recombinant human bone morphogenetic protein-2 (rhBMP-2) dose on alveolar ridge augmentation and dental implant osseointegration. Bilateral, 5 mm supraalveolar, peri-implant defects were surgically created in 6 beagle dogs. rhBMP-2 (0.05. 0.1 or 0.2 mg/ml) in an absorbable collagen sponge (ACS) carrier was molded around the fixtures and wounds were closed. Treatment variations were alternated between animals (incomplete block design). Animals were sacrificed at week 8 postsurgery. Nine of twelve jaw quadrants healed uneventfully. Two jaw quadrants exhibited wound failure by week 4 and one by week 8 postsurgery. Radiographic bone regeneration was observed in defects without wound failure from week 4 postsurgery. Radiolucent voids of variable size and shape were observed and regressed over time. In weeks 6 through 8, there was an apparent increase in bone density and trabecular structure, while bone height and volume decreased. Histometric analysis revealed limited differences in bone regeneration between experimental conditions. Bone regeneration area averaged (±SD) 1.0 ± 0.5, 3.5 ± 1.4 and 2.3 ± 0.4 mm2 for the 0.05. 0.1 and 0.2 mg/ml dose, respectively. There were no significant differences in osseointegration. Osseointegration in newly formed bone averaged 19 ± 4%, 18 ± 10% and 21 ± 6% for the 0.05, 0.1 and 0.2 mg/ml rhBMP-2 sites, respectively. Collectively, the data suggest that there are no dramatic differences in bone induction and osseointegration within the selected dose and observation interval.

KW - Bone morphogenetic protein-2

KW - Bone regeneration, dental implants

KW - Dose-response

KW - Osseointegration

UR - http://www.scopus.com/inward/record.url?scp=0036548656&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036548656&partnerID=8YFLogxK

U2 - 10.1034/j.1600-0765.2002.00021.x

DO - 10.1034/j.1600-0765.2002.00021.x

M3 - Article

C2 - 12009189

AN - SCOPUS:0036548656

VL - 37

SP - 93

EP - 100

JO - Journal of Periodontal Research

JF - Journal of Periodontal Research

SN - 0022-3484

IS - 2

ER -